FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SALEKI-GERHARDT AZITA
2. Issuer Name and Ticker or Trading Symbol

AbbVie Inc. [ ABBV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Operations
(Last)          (First)          (Middle)

1 N. WAUKEGAN ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

5/24/2021
(Street)

NORTH CHICAGO, IL 60064
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value 5/24/2021  M  12400 A$29.23 128684 D  
Common Stock, $0.01 par value 5/24/2021  M  74520 A$35.88 203204 D  
Common Stock, $0.01 par value 5/24/2021  S  77863 D$116.2431 (1)125341 D  
Common Stock, $0.01 par value 5/24/2021  S  9057 D$116.7049 (2)116284 D  
Common Stock, $0.01 par value         2272 (3)I Profit sharing trust 
Common Stock, $0.01 par value         3873 (4)I By spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option (Right to buy) (5)$29.23 5/24/2021  M     12400  2/17/2013 2/16/2022 Common Stock 12400 $0 0 D  
Option (Right to buy) (5)$35.88 5/24/2021  M     74520  2/14/2014 2/13/2023 Common Stock 74520 $0 0 D  

Explanation of Responses:
(1) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3) Balance in AbbVie Savings program as of May 26, 2021.
(4) The reporting person disclaims beneficial ownership of all securities held by her spouse.
(5) Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:
The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
SALEKI-GERHARDT AZITA
1 N. WAUKEGAN ROAD
NORTH CHICAGO, IL 60064


EVP, Operations

Signatures
Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt5/26/2021
**Signature of Reporting PersonDate

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbbVie Charts.